<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02972229</url>
  </required_header>
  <id_info>
    <org_study_id>WuhanUH201610</org_study_id>
    <nct_id>NCT02972229</nct_id>
  </id_info>
  <brief_title>Whole Versus Partial Vertebral Body IMRT for Spinal Metastases</brief_title>
  <official_title>Whole Versus Partial Vertebral Body IMRT for Spinal Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the treatment effect and toxicity between Intensity-Modulated Radiation therapy&#xD;
      for whole metastatic vertebral body and simple metastatic lesions of vertebra in metastatic&#xD;
      spinal tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, single center, controlled explorative study in the&#xD;
      parallel-group design to evaluate the difference in clinical outcomes for patients with&#xD;
      metastatic spine disease treated with a whole versus partial vertebral body contouring&#xD;
      approach. Thereby two different techniques were evaluated: whole vertebral body (WB) group&#xD;
      with 10 x 3Gy or partial vertebral body (PB) group with 10x (3-5)Gy. Prior to their enrolment&#xD;
      into the study, the patients will undergo a staging of the vertebral column in connection&#xD;
      with their radiation-planning computed tomography (CT) and MRI to measure the myelon&#xD;
      dimension. After the baseline results have been recorded, the patients will be randomized&#xD;
      into one of the two groups: PB group RT 10x (3-5) Gy (n = 30) or WB group RT 10 x 3 Gy (n =&#xD;
      30). The target parameters will be measured and recorded at baseline, at 1 to 2 weeks; and at&#xD;
      months 2 to 3, 4 to 6 and 7 to 12 after treatment.&#xD;
&#xD;
      The primary endpoint was the time to pain relief. Secondary endpoints were quality of life&#xD;
      (QoL), fatigue, pain, overall survival, bone survival, local control, pathological fracture,&#xD;
      pain-free internal and neurological deficit. The baseline examination shall be carried out on&#xD;
      the first day of radiotherapy prior to the start of therapy and is scheduled to comprise the&#xD;
      comprehensive recording of the sociodemographic data, the recording of the current pain&#xD;
      situation, the quality of life, and the current degree of fatigue. The follow-up examinations&#xD;
      shall take place at each follow up visit , measuring those parameters recorded at the&#xD;
      baseline examination. The further follow-up examinations shall correspond to those carried&#xD;
      out as standard after-care investigations.&#xD;
&#xD;
      The secondary endpoints such as fatigue and quality of life shall be recorded using validated&#xD;
      questionnaires (EORTC QLQ FA13 and EORTC QLQ BM22. All patients will also be asked to record&#xD;
      their pain history using a pain diary (documentation of medication daily during treatment,&#xD;
      once weekly after the end of treatment, VAS pain scale). Furthermore, the local control was&#xD;
      assessed by means of CT images taken prior to, three and six months after RT. The pain&#xD;
      response was documented on the VAS (range 0-10). Complete response (CR) was defined as VAS =&#xD;
      0 after three and six months, partial response (PR) as an improvement by at least two score&#xD;
      points after three and six months. Overall survival (OS) was defined as time from initial&#xD;
      diagnosis until death, bone survival as time from initial diagnosis of spinal bone metastasis&#xD;
      until death.&#xD;
&#xD;
      In each case, the treatment plan was designed based on tumor geometry, proximity to the&#xD;
      spinal cord, and location. The planning tumor volume (PTV) was defined as equal to gross&#xD;
      tumor volume (GTV). The spinal cord, cauda equina, nerve roots, and bowel were contoured as&#xD;
      organs at risk (OARs) and critical structures. An inverse treatment planning method along&#xD;
      with a linear optimization algorithm were employed. The target volume was designated to&#xD;
      include either the GTV and the entire vertebral body (WB group) or only the GTV (PB group) at&#xD;
      each spinal level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the time to pain relief</measure>
    <time_frame>3 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life measured on an EORTC BM22 questionnaire</measure>
    <time_frame>3 and 6 months after therapy completed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control</measure>
    <time_frame>3 months after therapy completed</time_frame>
    <description>local control as bone density is assessed 12 weeks post completion of radiotherapy using follow-up CT scan of the spine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>partial body group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10x(3-5) Gy IMRT on partial vertebral body</description>
  </arm_group>
  <arm_group>
    <arm_group_label>whole body group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10x3 Gy IMRT on whole vertebral body</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>10x(3-5) Gy IMRT</intervention_name>
    <description>10x(3-5) Gy IMRT on partial vertebral body for spinal metastases</description>
    <arm_group_label>partial body group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>10x3 Gy IMRT</intervention_name>
    <description>10x3 Gy IMRT on whole vertebral body for spinal metastases</description>
    <arm_group_label>whole body group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a histologically confirmed tumor diagnosis, with secondary -diagnosed&#xD;
             solitary/multiple spinal bone metastases&#xD;
&#xD;
          -  Indication for RT of the spinal bone metastases&#xD;
&#xD;
          -  Maximal two irradiated vertebral-bodies per region&#xD;
&#xD;
          -  Maximal two different vertebral regions&#xD;
&#xD;
          -  Age: between 18 and 80 years&#xD;
&#xD;
          -  Karnofsky index (10) â‰¥ 70&#xD;
&#xD;
          -  Signed Declaration of Informed Consent&#xD;
&#xD;
          -  Tumor distance &gt; 3 mm to myelon&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple myeloma or lymphoma&#xD;
&#xD;
          -  Significant neurological or psychiatric disorders, including dementia and epileptic&#xD;
             seizures&#xD;
&#xD;
          -  Earlier RT at the current irradiated site&#xD;
&#xD;
          -  Other severe disorders that in the judgement of the study director may prevent the&#xD;
             patient's participation in the study&#xD;
&#xD;
          -  Lacking or diminished legal capacity&#xD;
&#xD;
          -  Any medical of psychological condition that the study director considers a preventive&#xD;
             factor for the patient's ability to complete the study or to adequately&#xD;
&#xD;
          -  understand the scope of the study and to give his/her consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Zhenwei Zou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

